Moleculin Biotech, Inc. Derivative Liability
Moleculin Biotech, Inc. (MBRX) had Derivative Liability of $743.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2017-11-13
- 2017-09-30: Derivative Liability $743.00K.
- 2017-06-30: Derivative Liability $1.19M.
- 2017-03-31: Derivative Liability $1.24M.
- 2016-12-31: Derivative Liability $0.00.
| Period end | Derivative Liability |
|---|---|
| 2017-09-30 | $743.00K 10-Q · filed 2017-11-13 |
| 2017-06-30 | $1.19M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $1.24M 10-Q · filed 2017-05-12 |
| 2016-12-31 | $0.00 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |